Evidence map›Paper›PMID 35652219›Full record

ArticleCancer discovery2022

Packing a Punch against PD-L1.

Claudia Capparelli, Andrew E Aplin

Abstract readEditorialComment
PubMed Publisher
In one paragraph

Article in Cancer discovery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Antibody-Empowered Nanomedicine for Precise Biomedical Applications.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Claudia CapparelliDepartment of Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania.
Andrew E AplinDepartment of Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania.ORCID 0000-0002-2734-3244

Funding

Request for Supplemental Funds aligned to CA160495R01CA160495 · NCI · THOMAS JEFFERSON UNIVERSITY · PI APLIN, ANDREW ERIC · 2012 to 2022
$3.6M
Targeted therapies in mutant BRAF melanomaR01CA182635 · NCI · THOMAS JEFFERSON UNIVERSITY · PI APLIN, ANDREW ERIC · 2014 to 2024
$3.4M
Targeting Systems Vulnerabilities in the Gαq/GNAQ Oncogenic Signaling Circuitry: New Precision Therapies for Uveal MelanomaR01CA257505 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI APLIN, ANDREW ERIC, GUTKIND, JORGE SILVIO · 2021 to 2025
$2.7M
Mechanisms of uveal melanoma dormancy and targeted therapy toleranceR01CA253977 · NCI · THOMAS JEFFERSON UNIVERSITY · PI AGUIRRE-GHISO, JULIO A., APLIN, ANDREW ERIC · 2020 to 2024
$2.4M
Mechanisms of cell death in cutaneous melanomaR01CA256945 · NCI · THOMAS JEFFERSON UNIVERSITY · PI ALNEMRI, EMAD S, APLIN, ANDREW ERIC · 2021 to 2025
$2.3M
B-RAF Regulation of the Cell Cycle in MelanomaR01CA125103 · NCI · THOMAS JEFFERSON UNIVERSITY · PI APLIN, ANDREW ERIC · 2008 to 2013
$1.4M
NCI NIH HHS R01 CA125103NCI NIH HHS R01 CA160495NCI NIH HHS R01 CA182635NCI NIH HHS R01 CA253977NCI NIH HHS R01 CA256945NCI NIH HHS R01 CA257505
6 · The paper itself

Abstract

summaryAntibodies targeting immune checkpoints have made major advances in cancer therapy, but their use can be limited by immune-related adverse effects. The introduction of small-molecule immune-checkpoint inhibitors represents an alternative to improve the current antibody-based immune therapies. See related article by Koblish et al., p. 1482 (3).

Indexed as

B7-H1 AntigenImmune Checkpoint InhibitorsHumansB7-H1 AntigenImmune Checkpoint Inhibitors

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.